Verition Fund Management’s Viking Therapeutics VKTX Stock Holding History

Verition Fund Management’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-112,737	Closed	-$3.97M	–	3601
2025 Q4	$3.97M	Buy	112,737 +98,999	+721%	+$3.51M	0.02%	1052
2025 Q3	$361K	Buy	+13,738	New	+$410K	﹤0.01%	3208
2025 Q2	–	Sell	-185,179	Closed	-$4.47M	–	3886
2025 Q1	$4.47M	Buy	185,179 +158,838	+603%	+$5.02M	0.02%	923
2024 Q4	$1.06M	Buy	26,341 +18,620	+241%	+$1.06M	﹤0.01%	2008
2024 Q3	$489K	Buy	7,721 +3,446	+81%	+$202K	﹤0.01%	2342
2024 Q2	$227K	Sell	4,275 -5,376	-56%	-$352K	﹤0.01%	2519
2024 Q1	$791K	Buy	+9,651	New	+$429K	0.01%	1748
2023 Q2	–	Sell	-73,443	Closed	-$1.22M	–	2577
2023 Q1	$1.22M	Buy	+73,443	New	+$759K	0.02%	874
2019 Q4	–	Sell	-109,117	Closed	-$751K	–	1387
2019 Q3	$751K	Sell	109,117 -64,183	-37%	-$477K	0.02%	489
2019 Q2	$1.44M	Buy	173,300 +162,960	+1,576%	+$1.39M	0.04%	317
2019 Q1	$103K	Buy	+10,340	New	+$86.5K	﹤0.01%	1023
2018 Q2	–	Sell	-11,546	Closed	-$50K	–	1339
2018 Q1	$50K	Buy	+11,546	New	+$63.9K	﹤0.01%	1075

Other funds holding VKTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Verition Fund Management's VKTX Position: Q1 2026 in Review

Verition Fund Management sold out of Viking Therapeutics (VKTX) in Q1 2026, closing a stake of 112,737 shares — an estimated $3.97M sold.

Verition Fund Management first reported a position in VKTX in Q1 2018 and held it in 12 quarters. The position peaked at $4.47M in Q1 2025. 413 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.

Verition Fund Management reported no remaining Viking Therapeutics position as of Q1 2026 after selling out during the quarter.
Verition Fund Management sold 112,737 Viking Therapeutics shares in Q1 2026, an estimated $3.97M.
Verition Fund Management first reported a position in Viking Therapeutics in Q1 2018 and held it in 12 quarters.
Verition Fund Management's Viking Therapeutics position peaked at $4.47M in Q1 2025.
413 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.

Based on Verition Fund Management's 13F filing for Q1 2026, filed 15 May 2026.